Dermatology specialist Galderma (SWX:GALD) on Thursday announced the publication of positive Phase III OLYMPIA 1 trial results for nemolizumab in JAMA Dermatology.

The drug demonstrated significant improvements in itch and skin lesions in patients with moderate-to-severe prurigo nodularis.

Nemolizumab, a first-in-class monoclonal antibody targeting IL-31, showed rapid and sustained relief from itch and sleep disturbance. The drug has already been approved by the US Food and Drug Administration (FDA) for the treatment of prurigo nodularis in adults and is currently under review by regulatory authorities worldwide for both prurigo nodularis and atopic dermatitis.